Vertex Pharmaceuticals Inc (VRTX : NASDAQ)
Common Stock
$553.15
USD
-5.73 (-1.03%)
Last updated: 2026-11-02
Follow VRTX
VRTX
Vertex Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-1.03%
1 Week
+6.89%
1 Month
+9.59%
YTD
+22.34%
Key Statistics
Market Cap
$141.65B
52W High
$568.67
52W Low
$406.67
P/E Ratio
32.55
50 Day MA
$523.21
200 Day MA
$479.21
Beta
0.28
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/2/2026 | $560.88 | $568.67 | $544.09 | $553.15 | $553.15 | 3,029,399 |
| 10/30/2026 | $550.73 | $563.80 | $549.89 | $558.88 | $558.88 | 3,030,000 |
| 10/29/2026 | $536.46 | $546.61 | $534.01 | $540.00 | $540.00 | 1,534,035 |
| 10/28/2026 | $514.45 | $534.94 | $513.37 | $529.69 | $529.69 | 1,236,254 |
| 10/27/2026 | $514.84 | $521.43 | $509.20 | $521.03 | $521.03 | 1,019,488 |
| 10/26/2026 | $526.86 | $529.66 | $509.33 | $517.49 | $517.49 | 1,189,035 |
| 10/23/2026 | $531.66 | $533.08 | $522.91 | $523.93 | $523.93 | 832,600 |
| 10/22/2026 | $527.18 | $537.81 | $521.29 | $535.17 | $535.17 | 1,596,492 |
| 10/21/2026 | $512.79 | $528.57 | $510.48 | $524.52 | $524.52 | 1,417,733 |
| 10/20/2026 | $507.89 | $515.74 | $505.00 | $514.65 | $514.65 | 1,226,005 |
Analyst Price Targets
Based on 32 analysts covering VRTX · as of Nov 2, 2026
Wall Street analysts forecast VRTX stock price to rise 3.3% over the next 12 months.
Consensus
Buy4.34 / 5.00
Avg. Target
US$571.46
+3.3% Upside
Current Price
US$553.15
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
27.6%
Annualized
90-Day Vol
28.9%
Annualized
Trend (90d)
+45.7%
Annualized drift
90d Mean
US$651.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$584.11 | US$531.00 – US$642.53 |
| 60 trading days | US$616.80 | US$539.00 – US$705.82 |
| 90 trading days | US$651.32 | US$552.18 – US$768.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Financials
- Revenue (TTM)
- $12.59B
- EBITDA
- $5.10B
- Profit Margin
- 35.00%
- ROE (TTM)
- 23.54%
- EPS (Diluted)
- 17.17
- Book Value
- 79.92
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About VRTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| VCIG | VCI Global Limited Ordinary Share | $8.16 | +4728.40% |
| RETO | ReTo Eco-Solutions Inc | $4.16 | +647.26% |
| BJDX | Bluejay Diagnostics Inc | $2.12 | +281.02% |
| INO | Inovio Pharmaceuticals Inc | $1.89 | +215.00% |
| CLRO | ClearOne Inc | $5.65 | +65.69% |
| INLF | INLIF LIMITED Ordinary Shares | $0.29 | +56.76% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.06 | +55.50% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $2.85 | +52.41% |
VRTX.US news timeline
14 articles covering VRTX.US, most recent first
Latest